Emergent Biosolutions Inc

+0.75 (+1.23%)
Other Pre-Announcement

Emergent Biosolutions Reports Qtrly Adjusted Earnings Per Share Of $1.53

Published: 04/29/2021 20:33 GMT
Emergent Biosolutions Inc (EBS) - Emergent Biosolutions Reports Financial Results for First Quarter 2021.
Sees Q2 Revenue $370 Million to $430 Million.
Revises 2021 Financialforecast.
Emergent - Even Assuming FDA Concurrence to Re-initiate New Manufacturing And/or Release of Lots, Expects a Delay in Timing of Expected Revenue.
Emergent - 2021 Revenue, Specifically Other Product Sales, Expected to Be Impacted Due to Assumption That a New Raxibacumab Contract Will Be Awarded Later.
Qtrly Earnings per Share $1.28.
Qtrly Adjusted Earnings per Share $1.53.
2021 Cdmo Services Revenue Reduced Primarily Due to Hold of Certain Covid-19 Vaccine Bulk Drug Substance Lots.
Sees FY Total Revenues $1,700 - $1,900 Million.
Sees FY Adjusted Net Income $395 - $470 Million.
Qtrly Total Revenues $343.0 Million Versus $192.5 Million.
Q2 Revenue View $502.3 Million -- Refinitiv Ibes Data (analyst estimates).
Q1 Earnings per Share View $1.12, Revenue View $358.5 Million -- Refinitiv Ibes Data (analyst estimates).
FY2021 Revenue View $2.00 Billion -- Refinitiv Ibes Data (analyst estimates).